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Prospects for Liposome-Encapsulated Nisin
in the Prevention of Dental Caries
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and Kazuo Yamakami
Abstract Dental caries is a common oral bacterial infectious disease. Its preven-
tion requires the control of the causative pathogens, such as Streptococcus mutans,
that exist within dental plaque. Nisin is a proteinaceous bacteriocin produced by
Lactococcus lactis that is used to suppress bacterial infections. It has an inhibitory
mode of action on a wide range of gram-positive bacteria. Improvements in the
medical benefits of antibacterial agents can be achieved if they can be retained in
liposomes for a long period after administration. Liposome systems can increase the
ability of the encapsulated compounds, which have been widely used to encapsulate
many kinds of compounds in various scientific settings. Liposomes can release
labile molecules at a moderate rate. Liposome technologies that effectively protect
the encapsulated molecules from decomposition have the potential to improve their
preventive and therapeutic effects. Therefore, the use of liposomes to administer
antimicrobial agents has spurred research into their utility in preventive medicine.
The encapsulation of nisin in liposomes can provide means of improving the
stability of nisin and its antibacterial effect against S. mutans. The present chapter
will review the prospects for liposome-encapsulated nisin for the prevention of oral
infectious diseases.
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Oral diseases related to cariogenic microorganisms, such as dental caries, affect
majority of the world’s populations [1]. Dental caries results from interaction of
specific bacteria with dietary carbohydrates in the oral cavity. Streptococcus
mutans is a key contributor to the formation of cariogenic glucan biofilms. Nisin
is an effective bactericidal agent against gram-positive bacteria [2]. It is a bacteri-
ocin with a molecular mass of 3,354 and is produced by certain strains of
Lactococcus lactis subsp. lactis [3]. The bactericidal activity of nisin against
cariogenic streptococci was investigated in vitro and the findings indicated that
nisin acts as an inhibitor of typical cariogenic streptococci [4, 5]. It may be possible
to use liposomes as a carrier for the effective administration of nisin. Liposomes are
artificial spherical vesicles that can be created from lipids. They have been devel-
oped and evaluated as carriers to deliver encapsulated molecules to target organs
and specific cells in vitro and in vivo [6–9]. Investigations on liposomes have led to
their use with many substances, and the encapsulated agents are pharmacodynam-
ically and pharmacokinetically much more efficient than the naked compounds.
Liposome-encapsulated substances have been used in various applications such as
to retain and control the release of antibacterial compounds [10, 11]. They have
been used to deliver pharmaceuticals, and their recent application in the preserva-
tion of foods by the encapsulation of nisin has spurred further research into their use
with food materials [12, 13]. With regard to liposome formulations, a variety of
factors, such as lipid composition, cholesterol content, the presence of a charge on
the lipid bilayer, and the size of the vesicle, affect the effectiveness of liposomes as
preventive and therapeutic agents [6]. Oral delivery of liposomal bacteriocins is a
useful for the treatment to prevent dental caries [5]. Encapsulation technologies,
which may shield substances such as nisin from degradation by digestive enzymes,
and effectively deliver the encapsulated contents at the same time, could be an
advancement in the field of preventive medicine [10].
This review article provides brief background information on liposomal nisin
and explores its possible applications with a focus on factors affecting its effec-
tiveness and the advantages it offers for human health by preventing dental caries.
26.2 Cariogenic Microorganisms and Dental Caries
The oral cavity harbors many microorganisms that together constitute a complex
micro-ecological environment [14]. Dental caries, a chronic infectious disease, is
induced by cariogenic microorganisms such as Streptococcus spp. The key viru-
lence factors of the microorganisms, insoluble glucans, can be identified when they
colonize dental plaque on the surface of the teeth [4, 15]. S. mutans in particular has
been recognized as a decisive factor in dental caries. Insoluble glucans provide
specific binding sites for oral bacterial colonization of the tooth surface and confer
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structural integrity on the extracellular matrix, and therefore they are essential for
the formation and accumulation of dental glucan biofilms [16]. Because insoluble
glucans are synthesized by glucosyltransferases of S. mutans and these glucans
provide a matrix for dental plaque biofilm, the streptococcus is considered to
contribute to the formation of cariogenic biofilms [16, 17]. The streptococcus
tenaciously adheres to the glucan and is highly acidgenic and acid-tolerant; these
are critical virulence properties in the pathogenesis of dental caries [18]. Therefore,
dental caries results from the interaction of S. mutans with dietary carbohydrates in
the oral cavity; the formation of insoluble glucan biofilms on the tooth surface is a
key result of the diet-bacterium interaction [19].
26.3 Nisin as a Tool for Preventive Medicine
Nisin is approved for use in foods and is employed as a food preservative in more
than 50 countries [20]. It belongs to a group of bactericidal peptides called type A
lantibiotics [21]. Two main natural variants of nisin, nisin A and nisin Z, have been
discovered [3]. Nisin Z is widely distributed and contains asparagine instead of
histidine at position 27 of the amino acid sequence of nisin A. The two variants have
nearly equal bactericidal activity, membrane insertion, and pore-forming ability.
Nisin is bactericidal against a broad range of gram-positive microorganisms, such
as Staphylococcus aureus and Listeria monocytogenes, and prevents the outgrowth
of many Clostridium spp. and Bacillus spp. [11, 13]. However, stability issues such
as proteolytic degradation and oxidation result in reduced bioactivity. It is soluble
and stable at acidic pH, but at alkaline pH values its solubility decreases and it
becomes biologically inactive [22]. Nisin is a peptide composed of 34 amino acids,
including one lanthionine, four β-methyl-lanthionine, one dehydrobutyrine, and
two dehydroalanine residues. The internal thioester rings formed by lanthionine
are responsible for the conformation of nisin [23]. The lanthionine rings act as
conserved binding motifs for the recognition of specific targets and create segments
of defined spatial structures in the nisin molecule [24]. The bactericidal activity of
nisin has been suggested to be a result of electrostatic interaction of the positively
charged carboxylterminal end of the molecule with negatively charged bacterial
membrane lipids [25].
Nisin antagonizes a broad spectrum of gram-positive bacteria [26, 27]. It has
dual activity against spore-forming bacteria, it inhibiting the outgrowth of spores
and killing cells in the vegetative state. The didehydro amino acid residues in nisin
interact with the membrane sulfhydryl groups of germinating spores [26]. Mem-
brane disruption is considered to be the result of incorporation of nisin into the
membrane and subsequent ion channel or pore formation [25]. Membrane potential
is abolished in sensitive gram-positive cells as a result of the efflux of K+, amino
acids and ATP through the membrane pores [28]. Subsequent leakage of ions
causes catastrophic changes in transmembrane potential and internal pH. Nisin
interacts with high-affinity pyrophosphate binding sites on the membrane-bound
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cell wall precursor Lipid II, leading to more effective formation of pores and
inhibition of cell wall peptidoglycan biosynthesis [25, 29]. From these investiga-
tions, it is evident that nisin should be an effective antibacterial agent [30, 31].
26.4 Nisin Against Cariogenic Streptococci
Some antimicrobial agents, such as chlorohexidine, triclosan, xylitol, and
cetylpyridinium chloride, have attracted interest as agents for prophylaxis against
dental caries by inhibiting the multiplication of cariogenic microorganisms in the
oral cavity [4]. However, these agents may cause some side effects such as
discoloration of the teeth and tongue, drug resistance, and low solubility
[4]. Because nisin is a lanthibiotic, unlike antibiotics, it does not produce drug
resistance or chiasmatic resistance [21]. The bactericidal ability of nisin against
cariogenic streptococci, such as S. mutans, has been investigated as a means of
preventing dental caries [4]. Findings suggest that nisin has a potential to be used as
a bactericidal agent to prevent dental caries. Liposomal nisin was shown to inhibit
S. mutans [5]. In addition, nisin did not appear to be toxic to normal human gingival
fibroblast and epithelial cells [32]. Therefore, nisin plays a role in inhibiting the
viability of cariogenic streptococci.
26.5 Liposomes as a Tool for Preventive Medicine
Liposomes are formulated from phospholipid bilayers and consist of colloidal
dispersions of lipids in aqueous buffers [33, 34]. Their formation is based on the
interactions between phospholipids and water molecules in which the polar
headgroups of phospholipids are exposed to the inner and outer aqueous phases
and the hydrophobic carbohydrate tails are forced to face each other in a bilayer
[12, 35]. Liposomal encapsulation has been shown to stabilize the encapsulated
compound against enzymatic degradation and chemical modification [36]. Lipo-
somes can encapsulate hydrophobic and hydrophilic molecules, prevent the
decomposition of the encapsulated molecules, and release the compound at desig-
nated target organs [37, 38]. The bioactivity of encapsulated molecules can be
maintained by the phospholipid vesicle until it is delivered to the target organ or
cells, where the contents will be released [9, 39]. Liposomes can range in size from
40–50 nm to 1–2 μm, depending on the method of formulation, lipid components,
and intended use [40]. One of the aims of liposome encapsulation in medicine is to
increase the therapeutic index of the bioactive material [36, 41]. Encapsulation
techniques have been developed in many fields because of the biocompatibility of
liposomes, i.e., its ability to encapsulate both hydrophilic and lipophilic molecules,
and its ability to deliver these molecules to target sites [42, 43]. In the food
industry, liposomes have been used to deliver antibiotics, peptides, vitamins, and
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flavors [44, 45]. The encapsulation of bacteriocins, such as nisin in liposomes
represents an alternative to overcome problems related to the exploitation of
bactericidal activities [5, 40]. Liposomes have been developed and used as carriers
for therapeutic agents to improve the delivery of many anticancer and antibiotic
compounds [46–48].
The usefulness of conservative therapeutics is restricted by their inability to
deliver compounds to target sites. Attempts have been made to overcome this
difficulty by providing selective delivery and release of encapsulated compounds.
Hydrophobic compounds can be directly encapsulated into liposomes during ves-
icle formation, and retention is governed by interactions between the compound and
lipid. Passive encapsulation of soluble compounds depends on the ability of lipo-
somes to trap aqueous buffer containing dissolved compounds during vesicle
formation [49]. The applications of liposomes in medicine and pharmacology can
be divided into therapeutic and preventive uses of liposomes composed of various
substances [9, 50, 51]. Advances in liposome design lead to applications for the
delivery of new technology products such as nucleotides involved in numerous
biological functions [48, 52]. There have been many studies on the viability of a
range of conservative chemicals formulated in liposomes, frequently resulting in
improved biological activity compared with that of the naked form. Many antibi-
otics are orally available and liposome encapsulation can be developed for labile
chemicals with minimal loss of utility. Therefore, liposomes are used in pharma-
ceutical applications and the encapsulated substances have enhanced efficacy
compared with the naked substances. Liposomes are achieving medical acceptance
because of the effective shelf life of labile molecules, slow and steady release of the
molecules, and delivery of the molecules to required locations [46]. In pharmaceu-
tical applications, liposomes offer drug delivery systems for therapeutic and pre-
ventive strategies [53].
26.6 Characteristics of Liposomes
The design of liposomal delivery systems accelerates the treatment on human
health [6]. The strategy for liposomes is the development of carrier systems with
the ability to deliver and release encapsulated compounds [54]. The characteristics
of liposomes in this regard depend on their lipid composition, surface charge, and
vesicular size. Because bilayer fluidity and rigidity can affect the release of
liposomal compounds, studies have been carried out on the effects of phospholipids
of different phase transition temperatures on fluidity and the effects of lipid
composition on rigidity of liposomes [55, 56]. Liposomes with many different
lipid compositions exist, and those that include phospholipids provide efficient
vesicles for individual applications [57].
The aim of lipid selection for liposomes is to provide stabilizing and encapsu-
lation abilities. Phosphatidylcholines have been selected for the preparation of
liposome vesicles in many settings. The amount of encapsulated content released
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from vesicles is proportional to the acyl chain length of the phosphatidylcholine.
Dimyristoylphosphatidylcholine (DMPC), dipalmitoylphosphatidylcholine (DPPC)
and distearoylphosphatidylcholine (DSPC) have longer saturated acyl chains
(14, 16, and 18 carbons, respectively) and their phase transition temperature
increases with increasing chain length [58]. The trend in the release of encapsulated
compounds from vesicles is in the order of DMPC>DPPC>DSPC, which reflects
the fluidity of vesicles composed of DMPC, DPPC, and DSPC with a phase
transition temperature of 23, 41, and 55 C respectively [57]. For example, the
configuration of DPPC is a highly ordered gel phase at room temperature; however,
above 41 C the lipid forms a liquid crystalline phase characterized by greater
packing disorder because of temperature-induced changes in acyl chain composition
[58]. Unsaturated phospholipid species show more permeable and fluidic bilayers,
but saturated phospholipids with long acyl chains form a rigid, rather impermeable
bilayer structure [33, 37].
The cholesterol in phosphatidylcholine-based liposomes can reduce liposome
permeability, because membrane permeability is dependent on fluidity and rigidity
[59]. Cholesterol interacts with fatty acids in liposomes by hydrogen bonding,
increasing the cohesiveness and mechanical strength of the vesicular membrane
[60]. For example, a comparison of nisin-containing phosphatidylcholine lipo-
somes and phosphatidylcholine plus cholesterol showed that cholesterol reduced
the release of nisin [38, 61]. The permeability of liposomes can be altered by
modifying the cholesterol concentration according to the intended application of
the liposomes [57, 62]. Sphingomyelin also increases the rigidity of the bilayer [6].
Therefore, the modification of liposomal composition enables the preparation of
preferred kinds of liposomes for various scientific settings.
The effect of charge on lipid behavior is governed by the surface charge density
of the liposomes, lipid head groups, and interactions between the encapsulated
content and lipid [63, 64]. Liposomes composed of charged polar lipids with higher
electrical charges are more stable than those composed of neutral polar lipids. A
surface charge on liposomes increases repulsive interactions and reduces the
frequency of liposome collisions [65]. With regard to control of the release of
encapsulated compounds from liposomes, the charge has been observed to affect
vesicle permeability [63]. The use of negatively charged liposomes containing
phosphatidylglycerol led to greater effectiveness of the encapsulated molecules
compared with the use of neutral or positively charged liposomes. Therefore,
potency of the release of encapsulated compounds has been shown to be regulated
by polymer size, lipid composition, and surface charge [65].
Liposomes can be used as carriers of many different kinds of compound, such as
peptides and nucleotides, because liposomes are spherical vesicles whose mem-
branes are composed of one or more phospholipid bilayers [66]. Phospholipid
vesicles are capable of encapsulating labile molecules, and the lipids that they are
composed are biodegradable and safe in vivo [67]. Liposome encapsulation of
therapeutic and cosmetic agents can extend their activity by improving their
stability and permeability and by providing targeted and timed release [68].
Labile compounds that are susceptible to proteolytic degradation, such as insulin,
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calcitonin, parathyroid hormone, and erythropoietin, were shown to have
improved pharmacological effects after oral administration when encapsulated in
liposomes [69]. Oral delivery of liposomal compounds is useful for preventive and
therapeutic treatments.
26.7 Characteristics of Liposome-Encapsulated Nisin
Nisin is a cationic, amphiphilic antimicrobial peptide that inhibits gram-positive
bacteria [30]. The encapsulation efficacy of nisin is higher in liposomes composed
of neutral zwitterionic phospholipids, such as phosphatidylcholine, compared
with liposomes composed of anionic phospholipids, such as phosphatidylglycerol
[40, 61]. The highest nisin encapsulation efficacy was achieved in liposomes having
low contents of negatively charged phospholipids and high contents of zwitterionic
phospholipids [70]. Encapsulation of positively charged nisin in anionic phospho-
lipids should result in association because of attractive electrostatic interactions,
whereas encapsulation in neutral liposomes should result in association because of
hydrophobic interactions [71]. The electrostatic interaction of nisin with negatively
charged membrane phospholipids is more pronounced than its interaction with
neutral phospholipids [25]. Cationic vesicles containing stearylamine showed
lower encapsulation efficiency when compared with other kind of vesicles, which
could result from electrostatic repulsion between positively charged nisin and
cationic vesicles [35]. The functional properties of liposomal nisin depend on the
interaction of nisin with the liposome membrane and with the bacterial cell mem-
brane. Such electrostatic interactions are considered to be the initial step in the
series of events leading to membrane pore formation [72]. Nisin proved to have
high penetration ability for anionic phospholipids and low penetration ability for
neutral phospholipids [71]. Nisin in liposomes composed of phosphatidylcholine
demonstrated the slowest release of nisin, whereas liposomes composed of phos-
phatidylcholine plus phosphatidylglycerol appeared to release efficiently [65].
Because nisin is positively charged at neutral pH, electrostatic interaction with
negatively charged phosphatidylglycerol was attractive and should have led to the
formation of unstable pores because of binding to the charged phospholipid head
groups of phosphatidylglycerol [25]. The activity of the encapsulated nisin is
expressed by providing relatively short-term effects by release of the encapsulated
nisin and long-term effects by deposition of lipid-membrane-immobilized nisin,
i.e., bactericidal activity [28]. Therefore, encapsulated nisin and membrane-
immobilized nisin provide a tool for inhibiting pathogenic microbes.
Regarding the applications of nisin, various studies have shown the efficiency of
liposome-encapsulated nisin in food models [12]. The encapsulation of nisin
improves its antimicrobial activity as a food preservative and for the prevention
of oral infectious diseases [73]. Liposomal nisin should be able to provide effective
long-term inhibition of the target microbe, S. mutans, and therefore preventing
dental caries [5]. The surface charge of the liposome influences the interaction
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between liposomal nisin and bacteria [63]. As the bacterial cell has a negative
charge, electrostatic repulsion is induced between the cell surface and liposomes
composed of phosphatidylglycerol, preventing direct contact of the liposome with
the microbes, and the subsequent release of nisin [61]. This assumption supports the
idea that interaction between liposomes and microbes improves membrane
fusion [73].
26.8 Liposome-Encapsulated Nisin as a Preventive
Agent for Oral and Dental Health
There are relatively few published data regarding liposome-encapsulated nisin for
the prevention of oral infectious diseases. There is a report that liposomal nisin
inhibited the viability of S. mutans in vitro [5]. The inhibition of streptococcal
viability led to the suppression of insoluble glucan formation by the streptococcus
[5]. Previous studies have reported the synergistic antibacterial effects of combi-
nations of antimicrobials, such as nisin plus ethylenediaminetetraacetic acid
(EDTA), against gram-negative pathogens [74]. The ability of EDTA to destabilize
the outer membrane of gram-negative bacteria by sequestering ions such as Ca2+
and Mg2+ is considered to enable nisin to access the cell membrane, thereby
increasing its inhibitory effect [74]. The feacibility of encapsulating nisin plus
EDTA in vesicles for the inhibition of L. monocytogenes and Escherichia coli
O157:H7 was investigated [43, 65]. Coencapsulation of nisin plus EDTA increased
the inhibitory potential of liposomes against gram-positive S. mutans and gram-
negative Porphyromonas gingivalis [40, 74]. These findings indicate that the
liposomal nisin plus EDTA can inhibit the both of which could prevent dental
caries and periodontitis.
26.9 Prospects for Liposome-Encapsulated Nisin
Encapsulation of nisin in liposome carrier provides long-lasting inhibition of the
oral pathogen S. mutans. The appropriate balancing of the lipid components of the
vesicles allows the construction of stable liposomal nisin that provides predictable
release of the bactericidal agent. The results obtained so far encourage the study of
liposomal nisin with the aim of developing potential tools for the prevention of
dental caries. We are focusing on the application of liposomal technology in order
to ascertain the bactericidal potential of liposomes as an effective carrier of nisin for
oral health in humans.
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